Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 1, 26 | Andolina Massimo | officer: Group Chief Financial Officer | 0 | — | |
Daily · Wilder smoothing
| May 6, 26 |
| Combes Michel |
| director |
| A-Award |
| 1,119 @ $169.93 |
| $190.2K |
| May 6, 26 | Geissler Werner | director | A-Award | 1,119 @ $169.93 | $190.2K |
| May 6, 26 | Morparia Kalpana | director | A-Award | 1,119 @ $169.93 | $190.2K |
| May 6, 26 | Harker Victoria D | director | A-Award | 1,119 @ $169.93 | $190.2K |
| May 6, 26 | Polet Robert | director | A-Award | 1,119 @ $169.93 | $190.2K |
| May 6, 26 | Bough Bonin | director | A-Award | 1,119 @ $169.93 | $190.2K |
| May 6, 26 | Hook Lisa | director | A-Award | 1,119 @ $169.93 | $190.2K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 54.94 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 59.67 | Oscillator | Neutral |
| Williams %R (14) | -38.94 | Oscillator | Neutral |
| MACD (12, 26, 9) | 2.75 (Hist -0.01) | Oscillator | Sell |
| Average Directional Index (14) | 19.08 (+DI 25.1 / -DI 28.1) | Trend | Neutral |
| EMA 20 | 197.78 | MA | Buy |
| SMA 20 | 197.03 | MA | Buy |
| EMA 50 | 193.64 | MA | Strong Buy |
| SMA 50 | 192.55 | MA | Strong Buy |
| SMA 200 | 180.88 | MA | Strong Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Q3 Net Revenue: $11.4 billion, up 5.5% in dollar terms and 7.1% organically.Q3 Gross Profit: Grew organically by more than 8%.Q3 Adjusted Operating Income: Exce
Philip Morris (PM) delivered a solid Q3, with EPS and revenue beats, and raised its dividend by 8.8% to $1.60 per share. Smoke-free revenue now exceeds 40%, but growth in IQOS slowed due to regulatory headwinds; cigarette pricing continues to drive top-line gains. U.S. revenue rose 22.7%, but profit growth lagged due to higher marketing spend defending ZYN amid intensifying competition and price wars.
Philip Morris maintains its 2026 earnings outlook despite geopolitical costs, as rising ZYN investments and smoke-free expansion pressure U.S. profitability.
Organic net revenue grew 7% in the third quarter of 2026. Philip Morris transitions ZYN cans from 15 to 20 pouches.
CNBC's “Squawk on the Street” team is joined by Philip Morris Group CEO Jacek Olczak to discuss the company's latest earnings results and why it is warning of an "increasing effect" on business from the Iran war.
Philip Morris International NYSE: PM reported third-quarter results marked by higher revenue, operating income and adjusted earnings per share, as growth in smoke-free products and resilient cigarette performance helped offset increased costs tied to geopolitical disruptions and U.S. investments.
Philip Morris beats Q3 earnings and revenue estimates on strong pricing and smoke-free demand, updates its 2026 EPS outlook and reports margin expansion.
Stock futures are moving higher, with the Nasdaq-100 Index (NDX) and Dow Jones Industrial Average (DJI) leading the charge
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 21, 2026 | 2.30 | 2.36 | Beat 2.6% | $11.44B |
| Jul 22, 2026 | 2.05 | 2.20 | Beat 7.3% | $11.19B |
| Apr 22, 2026 | 1.86 | 1.96 | Beat 5.4% | $10.15B |
| Feb 6, 2026 | 1.70 | 1.70 | Beat 0.0% | $10.36B |
| Oct 21, 2025 | 2.09 | 2.24 | Beat 7.2% | $10.85B |
| Jul 22, 2025 | 1.86 | 1.91 | Beat 2.7% | $10.14B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Oct 23, 2026 | 2026-10-23 07:07:20 | View |
| 8-K | Oct 21, 2026 | 2026-10-21 07:04:41 | View |
| 8-K | Sep 18, 2026 | 2026-09-18 08:04:53 | View |
| 8-K | Sep 8, 2026 | 2026-09-08 09:46:10 | View |
| 8-K | Sep 8, 2026 | 2026-09-08 07:37:21 | View |
| 8-K | Aug 24, 2026 | 2026-08-24 07:02:13 | View |
| 3 | Aug 3, 2026 | 2026-08-03 16:59:02 | View |
| 25-NSE | Aug 3, 2026 | 2026-08-03 09:40:42 | View |
| 10-Q | Jul 24, 2026 | 2026-07-24 06:44:40 | View |
| 8-K | Jul 22, 2026 | 2026-07-22 07:02:12 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | PM | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 29.2x | 20.2x · sector 38.2x | Discount |
| Forward P/E (FY26E) | 24.0x | EPS est. 8.35 | Discount |
| Price / Book | -39.4x | -17.2x | Elevated |
| Price / Sales | 7.2x | 5.0x | Elevated |
| EV / EBITDA | 18.8x | 14.3x | Elevated |
| Return on equity | -119.7% | — | Weak |
| Gross margin | 67.7% | 65.5% | In line |
| Debt / Equity | -5.99 | -4.12 | Conservative |
| Piotroski / Altman Z | 8/9 | Z 4.88 | Safe zone |
Discounted cash flow model
Current price $200.18
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 22, 26 | UBS | maintain | Neutral | Neutral |
| Oct 22, 26 | Needham | maintain | Buy | Buy |
| Sep 23, 26 | UBS | maintain | Neutral | Neutral |
| Jul 30, 26 | Citigroup | maintain | Buy | Buy |
| Jul 29, 26 | Barclays | maintain | Overweight | Overweight |
| Jul 23, 26 | Stifel | maintain | Buy | Buy |
| Jul 23, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 23, 26 | Needham | maintain | Buy | Buy |
| Jul 2, 26 | UBS | maintain | Neutral | Neutral |